Last update 01 Nov 2024

Recombinant staphylokinase-hirudin fusion protein(Academy of Military Medical Sciences)

Last update 01 Nov 2024

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Fusion protein

Synonyms-

Target

PLG x prothrombin x uPA

Mechanism

PLG stimulants(Plasminogen stimulants), prothrombin inhibitors(Prothrombin inhibitors), uPA stimulants(Urokinase plasminogen activator stimulants)

Therapeutic Areas

Cardiovascular Diseases

Active Indication-

Inactive Indication

Thromboembolism

Originator Organization

Academy of Military Medical Sciences

Active Organization-

Inactive Organization

Wuhan Optical Valley Humanwell Biological Pharmaceutical Co.

Academy of Military Medical Sciences

Drug Highest PhasePendingIND Application

First Approval Date-

Regulation-

100 Clinical Results associated with Recombinant staphylokinase-hirudin fusion protein(Academy of Military Medical Sciences)

100 Translational Medicine associated with Recombinant staphylokinase-hirudin fusion protein(Academy of Military Medical Sciences)

100 Patents (Medical) associated with Recombinant staphylokinase-hirudin fusion protein(Academy of Military Medical Sciences)

Literatures (Medical) associated with Recombinant staphylokinase-hirudin fusion protein(Academy of Military Medical Sciences)

01 Dec 2021·Thrombosis ResearchQ3 · MEDICINE

Thrombolytic and anticoagulant effects of a recombinant staphylokinase-hirudin fusion protein

Q3 · MEDICINE

Article

Author: Liu, Yubin ; Gong, Hao ; Ren, Keyun ; Yu, Aiping ; Zhang, Fan ; Tian, Lvming ; He, Kun ; Dong, Qiaoyan ; Huang, Junjie ; Wu, Chutse

A pure recombinant staphylokinase-hirudin fusion protein (SFH) was obtained by recombinant genetic engineering and purification techniques. The thrombolytic and anticoagulant activities of SFH were investigated using in vitro coagulation models and chromogenic assays. The results showed that intact SFH had targeted thrombolytic activity, and gained anticoagulant activity when cleaved by FXa. In addition, we investigated the pharmacodynamics of SFH in vivo using a variety of animal models, including a rat inferior vena cava thrombosis model, a rat coronary thrombosis model, a rabbit carotid artery thrombosis model and a canine coronary thrombosis model. We found that SFH had an obvious thrombolytic effect and could prevent and reduce re-embolization after thrombolysis and reduce the serious bleeding side effects caused by the combination of thrombolytic and anticoagulant drugs. The results suggest that SFH can be used for thrombolytic therapy in thromboembolic diseases.

Small

Engineered Microrobots for Targeted Delivery of Bacterial Outer Membrane Vesicles (OMV) in Thrombus Therapy

Article

Author: Tang, Menghuan ; Chen, Qiwei ; Wu, Song ; Jiao, Yanxiao ; Li, Yangyang ; Cong, Zhaoqing ; Thongpon, Phonpilas ; Xie, Leiming

AbstractIn the realm of thrombosis treatment, bioengineered outer membrane vesicles (OMVs) offer a novel and promising approach, as they have rich content of bacterial‐derived components. This study centers on OMVs derived from Escherichia coli BL21 cells, innovatively engineered to encapsulate the staphylokinase‐hirudin fusion protein (SFH). SFH synergizes the properties of staphylokinase (SAK) and hirudin (HV) to enhance thrombolytic efficiency while reducing the risks associated with re‐embolization and bleeding. Building on this foundation, this study introduces two cutting‐edge microrobotic platforms: SFH‐OMV@H for venous thromboembolism (VTE) treatment, and SFH‐OMV@MΦ, designed specifically for cerebral venous sinus thrombosis (CVST) therapy. These platforms have demonstrated significant efficacy in dissolving thrombi, with SFH‐OMV@H showcasing precise vascular navigation and SFH‐OMV@MΦ effectively targeting cerebral thrombi. The study shows that the integration of these bioengineered OMVs and microrobotic systems marks a significant advancement in thrombosis treatment, underlining their potential to revolutionize personalized medical approaches to complex health conditions.

100 Deals associated with Recombinant staphylokinase-hirudin fusion protein(Academy of Military Medical Sciences)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Thromboembolism	IND Application	CN	Academy of Military Medical Sciences	03 Apr 2013
Thromboembolism	IND Application	CN	Wuhan Optical Valley Humanwell Biological Pharmaceutical Co.	03 Apr 2013

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Recombinant staphylokinase-hirudin fusion protein(Academy of Military Medical Sciences)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation